Business
Exclusive partnership for cancer assay
Exclusive partnership for cancer assay.
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\n \nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n \n \n\n \n26 June 2024\n \nEDX Medical Group plc\n \nAQSE: EDX\n(\"EDX Medical\" or the \"Company\")\n \nEXCLUSIVE COMMERCIAL PARTNERSHIP FOR PIONEERING\nCANCER DRUGS RESPONSE ASSAY IN UK AND NORDICS\n \n \nCAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces today it has signed an exclusive distribution agreement with Curesponse Ltd (\"Curesponse\"), to market the cResponse™ cancer assay in the UK, Sweden, Finland, Norway and Denmark.\ncResponse™ is a groundbreaking platform that biologically assesses how an individual patient's living tumour tissue responds to selected medicines, identifying the most effective treatment options. It is the only clinical-grade technology providing biological response data for chemotherapy, targeted biologics, and immunotherapy drugs. This platform helps clinicians rapidly pinpoint optimal treatments, potentially saving lives, reducing treatment costs, and accelerating the discovery and development cycles for pharmaceutical companies seeking new cancer drugs.\n \nThe cResponse™ platform generates a report ranking selected cancer drugs based on their predicted effect on an individual patient's tumour, demonstrating over 90% accuracy in clinical trials. The test can be augmented with rapid genomic sequencing to identify additional drug candidates for functional analysis. The entire process is powered by proprietary technologies and advanced AI algorithms. The platform technology has been refined and calibrated using thousands of cancer tissues, demonstrating its clinical utility and effectiveness through hundreds of cases in Israel and the UK. The cResponse™ test is performed at a United Kingdom Accreditation Service (UKAS) accredited lab in London and has also earned a CE mark for Europe, underscoring its regulatory approval ...